Who are Columvi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lunsumio, Ocrevus, Gazyva, Mabthera, Mabthera, EPKINLY.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glofitamab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Columvi — Competitive Intelligence Brief

Columvi (glofitamab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific CD20-directed CD3 T Cell Engager [EPC]. Area: Oncology.

marketed Bispecific CD20-directed CD3 T Cell Engager [EPC] B-lymphocyte antigen CD20 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Columvi (glofitamab) — Roche. Columvi works by binding to the CD20 protein on B-cell lymphoma cells, triggering an immune response to destroy the cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Columvi TARGET	glofitamab	Roche	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20	2023-01-01
Lunsumio	MOSUNETUZUMAB	Roche	marketed		B-lymphocyte antigen CD20	2022-01-01
Ocrevus	OCRELIZUMAB	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2017-01-01
Gazyva	obinutuzumab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
Mabthera	rituximab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
Mabthera	rituxan	Roche	marketed	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
EPKINLY	EPCORITAMAB-BYSP	GENMAB US, INC.	marketed		B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific CD20-directed CD3 T Cell Engager [EPC] class)

· 1 drug in this class
GENENTECH INC · 1 drug in this class
Genmab Us, Inc. · 1 drug in this class
Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Columvi — Competitive Intelligence Brief. https://druglandscape.com/ci/glofitamab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab